Literature DB >> 22091123

2-Chloro-methyl-1-methyl-1,3-benzimidazole.

Jie Han, Jun Zhang, Qi Yang, Ming-Gao Zhao, Guang Fan.   

Abstract

The title compound, C(9)H(9)ClN(2), was prepared from the reaction of N-methyl-benzene-1,2-diamine and 2-chloro-acetic acid in boiling 6 M hydro-chloric acid. The benzimidazole unit is approximately planar, the largest deviation from the mean plane being 0.008 (1) Å. The Cl atom is displaced by 1.667 (2) Å from this plane. The methyl group is statistically disordered with equal occupancy.

Entities:  

Year:  2011        PMID: 22091123      PMCID: PMC3213546          DOI: 10.1107/S1600536811028376

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For the biological activity of benzimidazoles, see: Refaat (2010 ▶); Laryea et al. (2010 ▶); Horton et al. (2003 ▶); Ries et al. (2003 ▶); Spasov et al. (1999 ▶); Matsui et al. (1994 ▶); Porcari et al. (1998 ▶); Rath et al. (1997 ▶); Migawa et al. (1998 ▶). For a description of the Cambridge Structural Database, see: Allen (2002 ▶).

Experimental

Crystal data

C9H9ClN2 M = 180.63 Triclinic, a = 6.607 (2) Å b = 8.168 (2) Å c = 8.925 (3) Å α = 84.566 (3)° β = 79.682 (4)° γ = 68.134 (4)° V = 439.6 (2) Å3 Z = 2 Mo Kα radiation μ = 0.38 mm−1 T = 296 K 0.37 × 0.29 × 0.18 mm

Data collection

Bruker SMART APEX CCD diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2002 ▶) T min = 0.874, T max = 0.937 2191 measured reflections 1523 independent reflections 1361 reflections with I > 2σ(I) R int = 0.018

Refinement

R[F 2 > 2σ(F 2)] = 0.042 wR(F 2) = 0.122 S = 1.06 1523 reflections 109 parameters H-atom parameters constrained Δρmax = 0.20 e Å−3 Δρmin = −0.32 e Å−3 Data collection: SMART (Bruker, 2002 ▶); cell refinement: SAINT (Bruker, 2002 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEPIII (Burnett & Johnson, 1996 ▶) and ORTEP-3 for Windows (Farrugia, 1997 ▶); software used to prepare material for publication: SHELXL97. Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536811028376/dn2705sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536811028376/dn2705Isup2.hkl Supplementary material file. DOI: 10.1107/S1600536811028376/dn2705Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C9H9ClN2Z = 2
Mr = 180.63F(000) = 188
Triclinic, P1Dx = 1.365 Mg m3
Hall symbol: -P 1Mo Kα radiation, λ = 0.71073 Å
a = 6.607 (2) ÅCell parameters from 2191 reflections
b = 8.168 (2) Åθ = 2.3–25.1°
c = 8.925 (3) ŵ = 0.38 mm1
α = 84.566 (3)°T = 296 K
β = 79.682 (4)°Block, white
γ = 68.134 (4)°0.37 × 0.29 × 0.18 mm
V = 439.6 (2) Å3
Bruker SMART APEX CCD diffractometer1523 independent reflections
Radiation source: fine-focus sealed tube1361 reflections with I > 2σ(I)
graphiteRint = 0.018
φ and ω scansθmax = 25.1°, θmin = 2.3°
Absorption correction: multi-scan (SADABS; Bruker, 2002)h = −7→5
Tmin = 0.874, Tmax = 0.937k = −9→9
2191 measured reflectionsl = −10→10
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.042Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.122H-atom parameters constrained
S = 1.06w = 1/[σ2(Fo2) + (0.0552P)2 + 0.1656P] where P = (Fo2 + 2Fc2)/3
1523 reflections(Δ/σ)max < 0.001
109 parametersΔρmax = 0.20 e Å3
0 restraintsΔρmin = −0.32 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/UeqOcc. (<1)
C10.2259 (4)0.4372 (3)0.6995 (2)0.0610 (6)
H1A0.34240.47810.71090.073*
H1B0.09850.53930.67900.073*
C20.1665 (3)0.3458 (2)0.8432 (2)0.0498 (5)
C3−0.2214 (4)0.3954 (3)0.8004 (3)0.0666 (6)
H3A−0.34050.36380.85630.100*0.50
H3B−0.17880.34440.70170.100*0.50
H3C−0.26830.52150.78880.100*0.50
H3D−0.18460.45600.70820.100*0.50
H3E−0.34630.47540.86280.100*0.50
H3F−0.25680.29830.77570.100*0.50
C4−0.0294 (3)0.2393 (2)1.0212 (2)0.0488 (5)
C5−0.1859 (4)0.1843 (3)1.1144 (3)0.0600 (6)
H5−0.32420.20691.08850.072*
C6−0.1250 (4)0.0947 (3)1.2471 (3)0.0675 (6)
H6−0.22580.05741.31370.081*
C70.0842 (4)0.0581 (3)1.2848 (3)0.0673 (6)
H70.1198−0.00411.37510.081*
C80.2384 (4)0.1119 (3)1.1915 (2)0.0605 (6)
H80.37730.08711.21730.073*
C90.1803 (3)0.2046 (2)1.0572 (2)0.0495 (5)
Cl10.31643 (17)0.29247 (10)0.54306 (8)0.1088 (4)
N10.3008 (3)0.2749 (2)0.94299 (19)0.0535 (4)
N2−0.0342 (3)0.3294 (2)0.88264 (18)0.0498 (4)
U11U22U33U12U13U23
C10.0686 (13)0.0587 (12)0.0545 (12)−0.0238 (11)−0.0075 (10)0.0029 (10)
C20.0509 (11)0.0472 (10)0.0489 (11)−0.0161 (8)−0.0037 (8)−0.0048 (8)
C30.0599 (13)0.0680 (14)0.0736 (15)−0.0195 (11)−0.0252 (11)0.0030 (11)
C40.0505 (10)0.0436 (10)0.0495 (11)−0.0146 (8)−0.0031 (8)−0.0077 (8)
C50.0550 (12)0.0568 (12)0.0676 (14)−0.0235 (10)0.0018 (10)−0.0068 (10)
C60.0741 (15)0.0634 (13)0.0630 (14)−0.0314 (12)0.0101 (11)−0.0041 (11)
C70.0840 (16)0.0602 (13)0.0512 (12)−0.0235 (12)−0.0033 (11)0.0048 (10)
C80.0609 (13)0.0639 (13)0.0540 (12)−0.0198 (10)−0.0100 (10)0.0006 (10)
C90.0513 (11)0.0483 (10)0.0474 (10)−0.0173 (9)−0.0040 (8)−0.0042 (8)
Cl10.1675 (9)0.0837 (5)0.0523 (4)−0.0326 (5)0.0147 (4)−0.0069 (3)
N10.0494 (9)0.0588 (10)0.0518 (10)−0.0203 (8)−0.0065 (7)0.0006 (8)
N20.0465 (9)0.0509 (9)0.0520 (9)−0.0170 (7)−0.0082 (7)−0.0028 (7)
C1—C21.488 (3)C4—N21.377 (3)
C1—Cl11.786 (2)C4—C51.389 (3)
C1—H1A0.9700C4—C91.398 (3)
C1—H1B0.9700C5—C61.373 (3)
C2—N11.310 (3)C5—H50.9300
C2—N21.363 (3)C6—C71.397 (4)
C3—N21.453 (3)C6—H60.9300
C3—H3A0.9600C7—C81.373 (3)
C3—H3B0.9600C7—H70.9300
C3—H3C0.9600C8—C91.390 (3)
C3—H3D0.9600C8—H80.9300
C3—H3E0.9600C9—N11.393 (3)
C3—H3F0.9600
C2—C1—Cl1110.86 (15)H3B—C3—H3F56.3
C2—C1—H1A109.5H3C—C3—H3F141.1
Cl1—C1—H1A109.5H3D—C3—H3F109.5
C2—C1—H1B109.5H3E—C3—H3F109.5
Cl1—C1—H1B109.5N2—C4—C5131.59 (19)
H1A—C1—H1B108.1N2—C4—C9105.69 (17)
N1—C2—N2114.14 (18)C5—C4—C9122.71 (19)
N1—C2—C1123.36 (19)C6—C5—C4116.3 (2)
N2—C2—C1122.49 (18)C6—C5—H5121.9
N2—C3—H3A109.5C4—C5—H5121.9
N2—C3—H3B109.5C5—C6—C7121.9 (2)
H3A—C3—H3B109.5C5—C6—H6119.1
N2—C3—H3C109.5C7—C6—H6119.1
H3A—C3—H3C109.5C8—C7—C6121.5 (2)
H3B—C3—H3C109.5C8—C7—H7119.3
N2—C3—H3D109.5C6—C7—H7119.3
H3A—C3—H3D141.1C7—C8—C9117.9 (2)
H3B—C3—H3D56.3C7—C8—H8121.1
H3C—C3—H3D56.3C9—C8—H8121.1
N2—C3—H3E109.5C8—C9—N1130.36 (19)
H3A—C3—H3E56.3C8—C9—C4119.77 (19)
H3B—C3—H3E141.1N1—C9—C4109.87 (17)
H3C—C3—H3E56.3C2—N1—C9104.17 (16)
H3D—C3—H3E109.5C2—N2—C4106.13 (16)
N2—C3—H3F109.5C2—N2—C3128.34 (18)
H3A—C3—H3F56.3C4—N2—C3125.52 (17)
  10 in total

1.  The Cambridge Structural Database: a quarter of a million crystal structures and rising.

Authors:  Frank H Allen
Journal:  Acta Crystallogr B       Date:  2002-05-29

Review 2.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures.

Authors:  Douglas A Horton; Gregory T Bourne; Mark L Smythe
Journal:  Chem Rev       Date:  2003-03       Impact factor: 60.622

3.  Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives.

Authors:  Hanan M Refaat
Journal:  Eur J Med Chem       Date:  2010-03-25       Impact factor: 6.514

4.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

5.  Design, synthesis, and antiviral activity of alpha-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl)benzimidazoles.

Authors:  M T Migawa; J L Girardet; J A Walker; G W Koszalka; S D Chamberlain; J C Drach; L B Townsend
Journal:  J Med Chem       Date:  1998-04-09       Impact factor: 7.446

6.  Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.

Authors:  A R Porcari; R V Devivar; L S Kucera; J C Drach; L B Townsend
Journal:  J Med Chem       Date:  1998-04-09       Impact factor: 7.446

7.  Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.

Authors:  T Roth; M L Morningstar; P L Boyer; S H Hughes; R W Buckheit; C J Michejda
Journal:  J Med Chem       Date:  1997-12-19       Impact factor: 7.446

8.  Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells.

Authors:  Daniel Laryea; Joachim Gullbo; Anders Isaksson; Rolf Larsson; Peter Nygren
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

9.  Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.

Authors:  T Matsui; Y Nakamura; H Ishikawa; A Matsuura; F Kobayashi
Journal:  Jpn J Pharmacol       Date:  1994-02

10.  Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.

Authors:  Uwe J Ries; Henning W M Priepke; Norbert H Hauel; Sandra Handschuh; Gerhard Mihm; Jean M Stassen; Wolfgang Wienen; Herbert Nar
Journal:  Bioorg Med Chem Lett       Date:  2003-07-21       Impact factor: 2.823

  10 in total
  1 in total

1.  A novel thiazolidinediones ATZD2 rescues memory deficits in a rat model of type 2 diabetes through antioxidant and antiinflammation.

Authors:  Xuan-Kang Wang; Ting Sun; Yu-Jiao Li; Yu-Hong Wang; Yan-Jiao Li; Liu-Di Yang; Dan Feng; Ming-Gao Zhao; Yu-Mei Wu
Journal:  Oncotarget       Date:  2017-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.